Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020955 | 0.94 | HDAC4 (0.36) | HDAC4HDAC2HDAC8HDAC6GSTP1 | |
| SCHEMBL3994896 | 0.85 | KMT2A (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15226824 | 0.85 | KMT2A (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1523430 | 0.83 | — | — | |
| SCHEMBL3994898 | 0.83 | GSTP1 (0.36) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20440725 | 0.81 | HDAC4 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Methacrylic Acid SCHEMBL7616667 | 0.80 | KMT2A (0.38) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL999502 | 0.79 | KMT2A (0.40) | HDAC4HDAC2HDAC8HDAC6GSTP1 | |
| SCHEMBL20440728 | 0.79 | HDAC4 (0.39) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL147808 | 0.79 | HDAC4 (0.40) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874407-B1 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG ENTWICKLUNG UND DIAGNOSTIK GMB (DE) | 2015-09-09 | — | — | EP | disclosed |
| EP-1877141-B1 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST BACTERIA | BIOMAC PRIVATINSTITUT FUER MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG ENTWICKLUNG UND DIAGNOSTIK GM (DE) | 2013-06-12 | — | — | EP | disclosed |
| US-20100204161-A1 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use Against Bacteria | BIOMAC PRIVATINSTITUT FUR MEDIZINISHE UND ZAHMEDIZ FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20080300303-A1 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use As Anti-Fungal Agents | BIOMAC PRIVATINSTITUT FUER MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300303-A1 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use As Anti-Fungal Agents | GLO1, G6PD, GRHPR | HDAC3 2184/4885HDAC4 2302/4885HDAC1 2053/4885 |
| US-20100204161-A1 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use Against Bacteria | GLO1, G6PD, GRHPR | HDAC3 3257/4885HDAC4 3581/4885HDAC1 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.